Eyepoint Pharmaceuticals (EYPT) Releases Earnings Results, Beats Expectations By $0.02 EPS

Eyepoint Pharmaceuticals (NASDAQ:EYPT) announced its quarterly earnings results on Thursday. The company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02, Morningstar.com reports. The company had revenue of $2.44 million for the quarter, compared to analysts’ expectations of $0.66 million. Eyepoint Pharmaceuticals had a negative net margin of 2,622.93% and a negative return on equity of 193.49%.

Shares of EYPT stock traded up $0.02 during trading hours on Friday, reaching $2.48. The company had a trading volume of 1,160 shares, compared to its average volume of 326,682. Eyepoint Pharmaceuticals has a one year low of $1.05 and a one year high of $3.94. The firm has a market capitalization of $233.34 million, a PE ratio of -4.24 and a beta of 2.01. The company has a quick ratio of 2.57, a current ratio of 2.57 and a debt-to-equity ratio of 0.37.

A number of equities analysts have recently commented on EYPT shares. ValuEngine raised shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 13th. Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research note on Thursday, February 7th. Finally, HC Wainwright set a $5.00 price objective on shares of Eyepoint Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, January 4th.

Several hedge funds have recently made changes to their positions in EYPT. Northern Trust Corp purchased a new position in Eyepoint Pharmaceuticals during the second quarter valued at approximately $218,000. BlackRock Inc. purchased a new stake in shares of Eyepoint Pharmaceuticals in the second quarter valued at $304,000. California Public Employees Retirement System purchased a new stake in shares of Eyepoint Pharmaceuticals in the second quarter valued at $135,000. Vanguard Group Inc lifted its position in shares of Eyepoint Pharmaceuticals by 2.7% in the third quarter. Vanguard Group Inc now owns 1,798,708 shares of the company’s stock valued at $6,422,000 after acquiring an additional 47,361 shares in the last quarter. Finally, Private Advisor Group LLC purchased a new stake in shares of Eyepoint Pharmaceuticals in the third quarter valued at $134,000. Hedge funds and other institutional investors own 57.99% of the company’s stock.

WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2019/03/15/eyepoint-pharmaceuticals-eypt-releases-earnings-results-beats-expectations-by-0-02-eps.html.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.

Recommended Story: Preferred Stock

Earnings History for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply